ciprofloxacin has been researched along with ginsenoside rh2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; He, J; Liu, J; Lu, M; Sun, X; Sun, Y; Wang, G; Wang, Y; Zhang, J; Zhang, X; Zhou, F | 1 |
| Long, J; Lu, C; Pan, X; Sun, M; Wu, C; Zhu, C | 1 |
2 other study(ies) available for ciprofloxacin and ginsenoside rh2
| Article | Year |
|---|---|
Non-antibiotic agent ginsenoside 20(S)-Rh2 enhanced the antibacterial effects of ciprofloxacin in vitro and in vivo as a potential NorA inhibitor.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Drug Synergism; Ginsenosides; Male; Mice, Inbred ICR; Microbial Sensitivity Tests; Molecular Docking Simulation; Multidrug Resistance-Associated Proteins; Peritonitis; Protein Conformation; Pyronine; RNA, Messenger; Staphylococcal Infections; Staphylococcus aureus | 2014 |
PLGA microsphere-based composite hydrogel for dual delivery of ciprofloxacin and ginsenoside Rh2 to treat
Topics: Administration, Cutaneous; Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Delivery Systems; Drug Liberation; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Ginsenosides; HaCaT Cells; Humans; Hydrogels; Methicillin-Resistant Staphylococcus aureus; Mice; Microspheres; Polylactic Acid-Polyglycolic Acid Copolymer; Staphylococcal Skin Infections; Staphylococcus aureus | 2020 |